Formoterol for the Treatment of Chronic Obstructive Pulmonary Disease

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report). 2020.
   Google Scholar
• AndersonGP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci. 1993;52(26):2145–2160. doi:10.1016/0024-3205(93)90729-M8099696
   PubMed Web of Science ®Google Scholar
• CazzolaM, PageCP, CalzettaL, MateraMG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.  doi:10.1124/pr.111.00458022611179
   PubMed Web of Science ®Google Scholar
• LecaillonJB, KaiserG, PalmisanoM, MorganJ, Della CioppaG. Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder inhalation via Aerolizer. Eur J Clin Pharmacol. 1999;55(2):131–138. doi:10.1007/s00228005060710335908
   PubMed Web of Science ®Google Scholar
• NialsAT, BallDI, ButchersPR, et al. Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol. 1994;251(2–3):127–135. doi:10.1016/0014-2999(94)90392-18149969
   PubMed Web of Science ®Google Scholar
• BouyssouT, CasarosaP, NalineE, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334(1):53–62. doi:10.1124/jpet.110.16700720371707
   PubMed Web of Science ®Google Scholar
• SlackRJ, BarrettVJ, MorrisonVS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218–230. doi:10.1124/jpet.112.19848123131596
   PubMed Web of Science ®Google Scholar
• BenhamouD, CuvelierA, MuirJF, et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med. 2001;95(10):817–821. doi:10.1053/rmed.2001.116111601748
   PubMed Web of Science ®Google Scholar
• RichterK, StengleinS, MuckeM, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration. 2006;73(4):414–419. doi:10.1159/00009199616534180
   PubMed Web of Science ®Google Scholar
• Bodzenta-LukaszykA, DymekA, McAulayK, MansikkaH. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11:28. doi:10.1186/1471-2466-11-2821605396
   PubMed Web of Science ®Google Scholar
• MaltaisF, FergusonGT, FeldmanGJ, et al. A randomized, double-blind, double-dummy study of glycopyrrolate/formoterol fumarate metered dose inhaler relative to umeclidinium/vilanterol dry powder inhaler in COPD. Adv Ther. 2019;36(9):2434–2449. doi:10.1007/s12325-019-01015-331267366
   PubMed Web of Science ®Google Scholar
• CazzolaM, OraJ, Di PaoloA, PuxedduE, CalzettaL, RoglianiP. Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD. Pulm Pharmacol Ther. 2016;39:48–53. doi:10.1016/j.pupt.2016.06.00627344046
   PubMed Web of Science ®Google Scholar
• PalmqvistM, PerssonG, LazerL, RosenborgJ, LarssonP, LotvallJ. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997;10(11):2484–2489. doi:10.1183/09031936.97.101124899426083
   PubMed Web of Science ®Google Scholar
• RichterK, JanickiS, JorresRA, MagnussenH. Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. Eur Respir J. 2002;19(5):865–871. doi:10.1183/09031936.02.0022850212030726
   PubMed Web of Science ®Google Scholar
• CazzolaM, PaggiaroP, PalangeP, et al. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study. Clin Drug Investig. 2012;32(3):147–155. doi:10.2165/11630880-000000000-00000
   PubMed Web of Science ®Google Scholar
• WedzichaJA, SinghD, VestboJ, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108(8):1153–1162. doi:10.1016/j.rmed.2014.05.01324953015
   PubMed Web of Science ®Google Scholar
• KewKM, MavergamesC, WaltersJA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):CD010177. doi:10.1002/14651858.CD010177.pub224127118
   PubMed Web of Science ®Google Scholar
• GrossNJ, DonohueJF. Nebulized formoterol: a review of clinical efficacy and safety in COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:223–232. doi:10.2147/COPD.S1100620714376
   PubMedGoogle Scholar
• TashkinDP, RennardSI, MartinP, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000.  doi:10.2165/00003495-200868140-0000418778120
   PubMed Web of Science ®Google Scholar
• RennardSI, TashkinDP, McElhattanJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–565. doi:10.2165/00003495-200969050-0000419368417
   PubMed Web of Science ®Google Scholar
• FergusonGT, TashkinDP, Skärby T, et al. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: the 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study. Respir Med. 2017;132:31–41. doi:10.1016/j.rmed.2017.09.00229229103
   PubMed Web of Science ®Google Scholar
• FergusonGT, PapiA, AnzuetoA, et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018;52(3):1801334. doi:10.1183/13993003.01334-201830220648
   PubMed Web of Science ®Google Scholar
• CalverleyPM, KunaP, MonsoE, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858–1868. doi:10.1016/j.rmed.2010.09.00820965712
   PubMed Web of Science ®Google Scholar
• TashkinDP, DohertyDE, KerwinE, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012;7:73–86.  doi:10.2147/COPD.S2944422334770
   PubMed Web of Science ®Google Scholar
• VogelmeierC, PaggiaroPL, DorcaJ, et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a Phase 3 COPD study. Eur Respir J. 2016;48(4):1030–1039. doi:10.1183/13993003.00216-201627492833
   PubMed Web of Science ®Google Scholar
• FergusonGT, Rodriguez-RoisinR, ReisnerC, MaesA, SiddiquiS, MartinUJ. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:945–953. doi:10.2147/COPD.S15498829606861
   PubMed Web of Science ®Google Scholar
• ReisnerC, FabbriLM, KerwinEM, et al. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel co-suspension delivery technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respir Res. 2017;18(1):8.  doi:10.1186/s12931-016-0491-828061907
   PubMed Web of Science ®Google Scholar
• TashkinDP, MartinezFJ, Rodriguez-RoisinR, et al. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016;120:16–24.  doi:10.1016/j.rmed.2016.09.01227817811
   PubMed Web of Science ®Google Scholar
• ReisnerC, PearleJ, KerwinEM, RoseES, DarkenP. Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1965–1977. doi:10.2147/COPD.S16645529950826
   PubMed Web of Science ®Google Scholar
• MartinezFJ, RabeKF, FergusonGT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357. doi:10.1016/j.chest.2016.11.02827916620
   PubMed Web of Science ®Google Scholar
• HananiaNA, TashkinDP, KerwinEM, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105–115. doi:10.1016/j.rmed.2017.03.01528427541
   PubMed Web of Science ®Google Scholar
• LipworthBJ, CollierDJ, GonY, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018;13:2969–2984.  doi:10.2147/COPD.S17183530310273
   PubMed Web of Science ®Google Scholar
• MartinezFJ, RabeKF, LipworthBJ, et al. Glycopyrrolate/formoterol fumarate metered dose inhaler improves lung function versus monotherapies in GOLD category a patients with COPD: pooled data from the phase III PINNACLE studies. Int J Chron Obstruct Pulmon Dis. 2020;15:99–106. doi:10.2147/COPD.S22979432021148
   PubMed Web of Science ®Google Scholar
• D’UrzoAD, RennardSI, KerwinEM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res. 2014;15(1):123. doi:10.1186/s12931-014-0123-025756831
   PubMed Web of Science ®Google Scholar
• SinghD, JonesPW, BatemanED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014;14:178. doi:10.1186/1471-2466-14-17825404569
   PubMed Web of Science ®Google Scholar
• BatemanED, ChapmanKR, SinghD, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16(1):92. doi:10.1186/s12931-015-0250-226233481
   PubMed Web of Science ®Google Scholar
• MiravitllesM, ChapmanKR, ChuecosF, RiberaA, GilEG. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis. Int J Chron Obstruct Pulmon Dis. 2016;11:2041–2053. doi:10.2147/COPD.S11456627621610
   PubMed Web of Science ®Google Scholar
• D’UrzoAD, SinghD, DonohueJF, et al. Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT. Int J Chron Obstruct Pulmon Dis. 2019;14:479–491. doi:10.2147/COPD.S18550230880938
   PubMed Web of Science ®Google Scholar
• SethiS, KerwinE, WatzH, et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:667–682. doi:10.2147/COPD.S18913830962681
   PubMed Web of Science ®Google Scholar
• SinghD, PapiA, CorradiM, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X27598678
   PubMed Web of Science ®Google Scholar
• VestboJ, PapiA, CorradiM, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• PapiA, VestboJ, FabbriL, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. doi:10.1016/S0140-6736(18)30206-X29429593
   PubMed Web of Science ®Google Scholar
• FergusonGT, ReisnerC, PearleJ, DePetrilloP, MaesA, MartinUJ. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology. Pulm Pharmacol Ther. 2018;49:67–74. doi:10.1016/j.pupt.2018.01.00729567116
   PubMed Web of Science ®Google Scholar
• RabeKF, MartinezFJ, FergusonGT, et al. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: the ETHOS study protocol. Respir Med. 2019;158:59–66. doi:10.1016/j.rmed.2019.08.01031605923
   PubMed Web of Science ®Google Scholar
• RabeKF, MartinezFJ, FergusonGT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa191604632579807
   PubMed Web of Science ®Google Scholar
• AndreasS, BothnerU, TrampischM, HaenselM, BuhlR, AlterP. Effect of long-acting beta2-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients. Pulm Pharmacol Ther. 2018;52:1–6. doi:10.1016/j.pupt.2018.08.00230077810
   PubMed Web of Science ®Google Scholar
• MannM, ChowdhuryB, SullivanE, NicklasR, AnthraciteR, MeyerRJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124(1):70–74. doi:10.1378/chest.124.1.7012853504
   PubMed Web of Science ®Google Scholar
• SYMBICORT® (budesonide and formoterol fumarate dihydrate) [package insert]. Dunkerque, France: AstraZeneca Dunkerque Production; 12 2017.
   Google Scholar
• TashkinDP, StrangeC. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601. doi:10.2147/COPD.S17224030214177
   PubMed Web of Science ®Google Scholar
• JansonC, LarssonK, LisspersKH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306. doi:10.1136/bmj.f330623719639
   PubMed Web of Science ®Google Scholar
• FergusonGT, RabeKF, MartinezFJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.  doi:10.1016/S2213-2600(18)30327-830232048
   PubMed Web of Science ®Google Scholar
• KerwinEM, FergusonGT, MoM, DeAngelisK, DorinskyP. Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study. Respir Res. 2019;20(1):167. doi:10.1186/s12931-019-1126-731358008
   PubMed Web of Science ®Google Scholar
• LotvallJ. Pharmacology of bronchodilators used in the treatment of COPD. Respir Med. 2000;94(suppl E):S6–10. doi:10.1016/S0954-6111(00)90155-011001072
   PubMed Web of Science ®Google Scholar
• ZafarMA, DroegeC, FoertschM, PanosRJ. Update on ultra-long-acting beta agonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2014;23(12):1687–1701. doi:10.1517/13543784.2014.942730
   PubMed Web of Science ®Google Scholar
• FORADIL AEROLIZER® (formoterol fumarate inhalation powder) [package insert]. Basle, Switzerland: Novartis Pharma AG; 9 2012.
   Google Scholar
• UTIBRON™ NEOHALER® (indacaterol and glycopyrrolate) [package insert]. Stein, Switzerland: Novartis Pharma Stein AG; 10 2015.
   Google Scholar
• STIOLTO® RESPIMAT® (tiotropium bromide and olodaterol inhalation spray) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 8 2020.
   Google Scholar
• SEREVENT DISKUS (salmeterol xinafoate inhalation powder) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 1 2020.
   Google Scholar
• BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 1 2019.
   Google Scholar